Novel ADCs in Advanced Breast Cancer

CME

Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: March 20, 2024

Expiration: March 19, 2025

Melinda Telli
Melinda Telli, MD
Sara M. Tolaney
Sara M. Tolaney, MD, MPH

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 53-year-old woman with a history of T2N1M1 grade 2 ILC of left breast (ER positive, PgR positive, HER2 IHC 1+; FISH ratio 1.1). At diagnosis, she had biopsy-proven metastatic disease involving mediastinal lymph nodes (ER positive, PgR positive, HER2 IHC 0; FISH ratio 1.2). NGS revealed PIK3CA and CDH1 mutations, no pathogenic germline variants. She received letrozole and ribociclib followed by fulvestrant and alpelisib but experienced disease progression. She received weekly paclitaxel. Restaging scans show disease progression with peritoneal carcinomatosis and pleural thickening. Biopsy showed ER positive/PgR positive; HER2 IHC 0 (FISH ratio 1.1).

What is the next best FDA-approved treatment option for this patient?